# Nouscom

Source: https://onco.cc/companies/nouscom/  
OnCo record `nouscom` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Nouscom is developing Nous-209, an off-the-shelf viral-vector vaccine encoding 209 shared frameshift neoantigens to intercept cancer in Lynch syndrome carriers.

## Summary

Nouscom, based in Basel and Rome, is developing Nous-209, an off-the-shelf viral-vector vaccine encoding 209 shared frameshift neoantigens, to intercept cancer in people with Lynch syndrome. A phase 1b/2 in Lynch carriers, published in Nature Medicine in March 2026, showed safety and immune responses in most participants, re-treatment and long-term follow-up data were selected for an ESMO 2026 oral, and the vaccine has also been tested with pembrolizumab in microsatellite-instability-high tumours. OnCo links it to colorectal cancer, to off-the-shelf cancer vaccines and chemoprevention, to the MSI-H and neoantigen terms, and to the idea of a randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers. Whether immune responses translate into fewer cancers in carriers is the question only a prevention trial can answer. The off-the-shelf vaccine page carries the field.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- HQ: Basel / Rome
- Type: biotech
- Website: https://nouscom.com

## Sources

- Nature Medicine 2026: https://www.nature.com/articles/s41591-025-04182-9

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/), [Off-the-shelf cancer vaccines](https://onco.cc/technologies/shared-antigen-vaccine/)
- terms: [Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR)](https://onco.cc/terms/msi/), [Neoantigen](https://onco.cc/terms/neoantigen/)
- trials: [Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors](https://onco.cc/trials/nct04041310/)
- companies: [Andera Partners](https://onco.cc/companies/andera-partners/)
- ideas: [A randomised trial of a shared-antigen vaccine to prevent Lynch syndrome cancers](https://onco.cc/ideas/idea-prev-lynch-frameshift-vaccine-rct/)

---
JSON: https://onco.cc/api/v1/entities/nouscom.json